The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Enhanced survival benefits in metastatic esophageal and gastric carcinoma
Eric Raymond, MD, Paris Saint-Joseph Hospital, Paris, France, discusses the findings of the TRIO-013/LOGiC trial (NCT00680901), investigating lapatinib with capecitabine and oxaliplatin. This trial focuses on patients with metastatic esophageal carcinoma, including both squamous cell and adenocarcinoma types, as well as gastric carcinoma. An increase in overall survival (OS) was seen in patients, with promising hazard ratios when compared to placebo. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
